Enabling CAR-T cells for solid tumors: Rage against the suppressive tumor microenvironment.

No abstract is available for this paper.

• Publication year

  2022

• Venue

  International Review of Cell and Molecular Biology

• Publication date

  Unknown publication date

• Fields of study

  Biology, Medicine

• Identifiers
  DOI 10.1016/bs.ircmb.2022.03.004PMID 35798503
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Harnessing cytokines and chemokines for cancer therapy

  2022cited by this paper
• The allergy mediator histamine confers resistanceto immunotherapy in cancer patients via activationof the macrophage histamine receptor H1.

  2021cited by this paper
• CAR-T cell-mediated depletion of immunosuppressive tumor-associated macrophages promotes endogenous antitumor immunity and augments adoptive immunotherapy

  2021cited by this paper
• Cancer-Associated Fibroblast Heterogeneity: A Factor That Cannot Be Ignored in Immune Microenvironment Remodeling

  2021cited by this paper
• Axicabtagene ciloleucel in relapsed or refractory indolent non-Hodgkin lymphoma (ZUMA-5): a single-arm, multicentre, phase 2 trial.

  2021cited by this paper
• Tissue-resident macrophages provide a pro-tumorigenic niche to early NSCLC cells

  2021cited by this paper
• Myeloid-derived suppressor cells in the era of increasing myeloid cell diversity

  2021cited by this paper
• Tim-4+ cavity-resident macrophages impair anti-tumor CD8+ T cell immunity.

  2021cited by this paper
• Discovering dominant tumor immune archetypes in a pan-cancer census.

  2021cited by this paper
• Conserved pan-cancer microenvironment subtypes predict response to immunotherapy.

  2021cited by this paper
• Navigating CAR-T cells through the solid-tumour microenvironment

  2021cited by this paper
• Heme catabolism by tumor-associated macrophages controls metastasis formation

  2021cited by this paper
• Live tumor imaging shows macrophage induction and TMEM-mediated enrichment of cancer stem cells during metastatic dissemination

  2021cited by this paper
• Chemokines and the immune response to cancer.

  2021cited by this paper
• Sialic acids in pancreatic cancer cells drive tumour-associated macrophage differentiation via the Siglec receptors Siglec-7 and Siglec-9

  2021cited by this paper
• Idecabtagene Vicleucel in Relapsed and Refractory Multiple Myeloma.

  2021cited by this paper
• A pan-cancer single-cell transcriptional atlas of tumor infiltrating myeloid cells.

  2021cited by this paper
• Selectively targeting myeloid-derived suppressor cells through TRAIL receptor 2 to enhance the efficacy of CAR T cell therapy for treatment of breast cancer

  2021cited by this paper
• Therapeutic Targeting of the Tumor Microenvironment.

  2021cited by this paper
• Myeloid-Derived Suppressor Cells: A Propitious Road to Clinic.

  2021cited by this paper
• Fibroblast Activation Protein-α as a Target in the Bench-to-Bedside Diagnosis and Treatment of Tumors: A Narrative Review

  2021cited by this paper
• VEGFR-2 redirected CAR-T cells are functionally impaired by soluble VEGF-A competition for receptor binding

  2021cited by this paper
• Fibroblast Activation Protein (FAP)-Targeted CAR-T Cells: Launching an Attack on Tumor Stroma

  2021cited by this paper
• A phase I trial of regional mesothelin-targeted CAR T-cell therapy in patients with malignant pleural disease, in combination with the anti-PD-1 agent pembrolizumab.

  2021cited by this paper
• Locoregional infusion of HER2-specific CAR T cells in children and young adults with recurrent or refractory CNS tumors: an interim analysis

  2021cited by this paper
• A framework for advancing our understanding of cancer-associated fibroblasts

  2020cited by this paper
• KTE-X19 CAR T-Cell Therapy in Relapsed or Refractory Mantle-Cell Lymphoma.

  2020cited by this paper
• Locoregionally administered B7-H3-targeted CAR T cells for treatment of atypical teratoid/rhabdoid tumors

  2020cited by this paper
• Single-cell analysis reveals fibroblast clusters linked to immunotherapy resistance in cancer.

  2020cited by this paper
• Distinct fibroblast functional states drive clinical outcomes in ovarian cancer and are regulated by TCF21

  2020cited by this paper
• 41BB-based and CD28-based CD123-redirected T-cells ablate human normal hematopoiesis in vivo

  2020cited by this paper
• Lisocabtagene maraleucel for patients with relapsed or refractory large B-cell lymphomas (TRANSCEND NHL 001): a multicentre seamless design study.

  2020cited by this paper
• Challenges and Opportunities for Pancreatic Cancer Immunotherapy.

  2020cited by this paper
• Real-world evidence of tisagenlecleucel for pediatric acute lymphoblastic leukemia and non-Hodgkin lymphoma.

  2020cited by this paper
• CAR-T Cells Hit the Tumor Microenvironment: Strategies to Overcome Tumor Escape

  2020cited by this paper
• The immune contexture and Immunoscore in cancer prognosis and therapeutic efficacy

  2020cited by this paper
• Tissue-resident macrophages in omentum promote metastatic spread of ovarian cancer

  2020cited by this paper
• Targeting immunosuppressive macrophages overcomes PARP inhibitor resistance in BRCA1-associated triple-negative breast cancer

  2020cited by this paper
• Determinants of Resident Tissue Macrophage Identity and Function.

  2020cited by this paper
• CAF hierarchy driven by pancreatic cancer cell p53-status creates a pro-metastatic and chemoresistant environment via perlecan

  2019cited by this paper
• Engineering strategies to overcome the current roadblocks in CAR T cell therapy

  2019cited by this paper
• Single-cell RNA sequencing reveals stromal evolution into LRRC15+ myofibroblasts as a determinant of patient response to cancer immunotherapy.

  2019cited by this paper
• TEM8/ANTXR1-specific CAR T cells mediate toxicity in vivo

  2019cited by this paper
• CD24 signalling through macrophage Siglec-10 is a new target for cancer immunotherapy

  2019cited by this paper
• Blocking Triggering Receptor Expressed on Myeloid Cells‐1‐Positive Tumor‐Associated Macrophages Induced by Hypoxia Reverses Immunosuppression and Anti‐Programmed Cell Death Ligand 1 Resistance in Liver Cancer

  2019cited by this paper
• Cross-species single-cell analysis of pancreatic ductal adenocarcinoma reveals antigen-presenting cancer-associated fibroblasts.

  2019cited by this paper
• Comprehensive Profiling of Poor-Risk Paired Primary and Recurrent Triple-Negative Breast Cancers Reveals Immune Phenotype Shifts

  2019cited by this paper
• Differential Effects of Depleting versus Programming Tumor-Associated Macrophages on Engineered T Cells in Pancreatic Ductal Adenocarcinoma

  2019cited by this paper
• Metastatic breast cancers have reduced immune cell recruitment but harbor increased macrophages relative to their matched primary tumors

  2019cited by this paper
• Nanobody-based CAR T cells that target the tumor microenvironment inhibit the growth of solid tumors in immunocompetent mice

  2019cited by this paper
• Human Tumor-Associated Macrophage and Monocyte Transcriptional Landscapes Reveal Cancer-Specific Reprogramming, Biomarkers, and Therapeutic Targets

  2019cited by this paper
• Therapeutic targeting of macrophages enhances chemotherapy efficacy by unleashing type I interferon response

  2019cited by this paper
• Siglec-15 as an immune suppressor and potential target for normalization cancer immunotherapy

  2019cited by this paper
• Macrophages as regulators of tumour immunity and immunotherapy

  2019cited by this paper
• NK Cells Expressing a Chimeric Activating Receptor Eliminate MDSCs and Rescue Impaired CAR-T Cell Activity against Solid Tumors

  2019cited by this paper
• Approaches to treat immune hot, altered and cold tumours with combination immunotherapies

  2019cited by this paper
• Tisagenlecleucel in Adult Relapsed or Refractory Diffuse Large B‐Cell Lymphoma

  2019cited by this paper
• Turning foes to friends: targeting cancer-associated fibroblasts

  2018cited by this paper
• Tumor Mutational Burden and Efficacy of Nivolumab Monotherapy and in Combination with Ipilimumab in Small-Cell Lung Cancer.

  2018cited by this paper
• T cell–induced CSF1 promotes melanoma resistance to PD1 blockade

  2018cited by this paper
• Patient HLA class I genotype influences cancer response to checkpoint blockade immunotherapy

  2018cited by this paper
• TGFβ drives immune evasion in genetically reconstituted colon cancer metastasis

  2018cited by this paper
• Tisagenlecleucel in Children and Young Adults with B‐Cell Lymphoblastic Leukemia

  2018cited by this paper
• Targeting macrophages: therapeutic approaches in cancer

  2018cited by this paper
• High-Dimensional Analysis Delineates Myeloid and Lymphoid Compartment Remodeling during Successful Immune-Checkpoint Cancer Therapy.

  2018cited by this paper
• Interleukin‐10 Directly Inhibits CD8+ T Cell Function by Enhancing N‐Glycan Branching to Decrease Antigen Sensitivity

  2018cited by this paper
• IL1-Induced JAK/STAT Signaling Is Antagonized by TGFβ to Shape CAF Heterogeneity in Pancreatic Ductal Adenocarcinoma.

  2018cited by this paper
• Macrophages of distinct origins contribute to tumor development in the lung

  2018cited by this paper
• Understanding the tumor immune microenvironment (TIME) for effective therapy

  2018cited by this paper
• Potent antitumor efficacy of anti-GD2 CAR T-cells in H3K27M+ diffuse midline gliomas

  2018cited by this paper
• Immune Cell Infiltration and Tertiary Lymphoid Structures as Determinants of Antitumor Immunity

  2018cited by this paper
• Targeting the tumour stroma to improve cancer therapy

  2018cited by this paper
• Co‐inhibitory Molecule B7 Superfamily Member 1 Expressed by Tumor‐Infiltrating Myeloid Cells Induces Dysfunction of Anti‐tumor CD8+ T Cells

  2018cited by this paper
• Targeting Tumor-Associated Macrophages as a Potential Strategy to Enhance the Response to Immune Checkpoint Inhibitors

  2018cited by this paper
• Adoptive Transfer of IL13Rα2-Specific Chimeric Antigen Receptor T Cells Creates a Pro-inflammatory Environment in Glioblastoma.

  2018cited by this paper
• CAR T cell immunotherapy for human cancer

  2018cited by this paper
• miR200-regulated CXCL12β promotes fibroblast heterogeneity and immunosuppression in ovarian cancers

  2018cited by this paper
• TGF-β attenuates tumour response to PD-L1 blockade by contributing to exclusion of T cells

  2018cited by this paper
• Cancer-Stimulated CAFs Enhance Monocyte Differentiation and Protumoral TAM Activation via IL6 and GM-CSF Secretion

  2018cited by this paper
• Host expression of PD-L1 determines efficacy of PD-L1 pathway blockade–mediated tumor regression

  2018cited by this paper
• Chimeric Antigen Receptor Therapy.

  2018cited by this paper
• Phenotype molding of stromal cells in the lung tumor microenvironment

  2018cited by this paper
• Dominant-Negative TGF-β Receptor Enhances PSMA-Targeted Human CAR T Cell Proliferation And Augments Prostate Cancer Eradication.

  2018cited by this paper
• Immunological differences between primary and metastatic breast cancer

  2018cited by this paper
• Spatially and functionally distinct subclasses of breast cancer-associated fibroblasts revealed by single cell RNA sequencing

  2018cited by this paper
• The Immune-microenvironment Confers Chemoresistance of Colorectal Cancer through Macrophage-Derived IL6

  2017cited by this paper
• Cancer-Associated Fibroblasts Neutralize the Anti-tumor Effect of CSF1 Receptor Blockade by Inducing PMN-MDSC Infiltration of Tumors.

  2017cited by this paper
• A neoantigen fitness model predicts tumour response to checkpoint blockade immunotherapy

  2017cited by this paper
• Microenvironmental regulation of tumour angiogenesis

  2017cited by this paper
• Myeloid‐derived cells in prostate cancer progression: phenotype and prospective therapies

  2017cited by this paper
• Overcoming the Immunosuppressive Tumor Microenvironment of Hodgkin Lymphoma Using Chimeric Antigen Receptor T Cells.

  2017cited by this paper
• Tumour-associated macrophages as treatment targets in oncology

  2017cited by this paper
• Chemokines in the cancer microenvironment and their relevance in cancer immunotherapy

  2017cited by this paper
• Axicabtagene Ciloleucel CAR T‐Cell Therapy in Refractory Large B‐Cell Lymphoma

  2017cited by this paper
• Tissue‐Resident Macrophages in Pancreatic Ductal Adenocarcinoma Originate from Embryonic Hematopoiesis and Promote Tumor Progression

  2017cited by this paper
• The role of myeloid cells in cancer therapies

  2016cited by this paper
• Effector T Cells Abrogate Stroma-Mediated Chemoresistance in Ovarian Cancer.

  2016cited by this paper
• Facilitating T Cell Infiltration in Tumor Microenvironment Overcomes Resistance to PD-L1 Blockade.

  2016cited by this paper
• The impact of hypoxia on tumor-associated macrophages.

  2016cited by this paper
• Mutations Associated with Acquired Resistance to PD-1 Blockade in Melanoma.

  2016cited by this paper

• Understanding the Cancer-Associated Fibroblast (CAF) and Its Biomarker Fibroblast Activation Protein (FAP), and Aspects in Human Liver Cancer.

  2025cites this paper
• Chimeric Antigen Receptor-Engineered (CAR)-T Cell Therapy for Metastatic Prostate Cancer.

  2025cites this paper
• Dual targeting chimeric antigen receptor cells enhance antitumour activity by overcoming T cell exhaustion in pancreatic cancer

  2024cites this paper
• Fibroblast activation protein constitutes a novel target of chimeric antigen receptor T‐cell therapy in solid tumors

  2024cites this paper
• FAP-targeted CAR-T suppresses MDSCs recruitment to improve the antitumor efficacy of claudin18.2-targeted CAR-T against pancreatic cancer

  2023cites this paper
• Updates on radiotherapy-immunotherapy combinations: Proceedings of 6th annual ImmunoRad conference

  2023cites this paper
• Modulation of Radiation Doses and Chimeric Antigen Receptor T Cells: A Promising New Weapon in Solid Tumors—A Narrative Review

  2023cites this paper
• Radiation therapy improves CAR T cell activity in acute lymphoblastic leukemia

  2023cites this paper
• TCR-engineered T cell therapy in solid tumors: State of the art and perspectives

  2023cites this paper
• Myeloid-derived suppressor cells: Emerging players in cancer and beyond.

  2023cites this paper
• CAR T-Cell therapy for the management of mantle cell lymphoma

  2023influential citation
• Radiotherapy plus CAR-T cell therapy to date: A note for cautions optimism?

  2022cites this paper
• Coexpression of c-Jun in multiple-chain DAP-CAR-engineered T-cells for solid tumor therapy.

  2022cites this paper